Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2017 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $47000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $47000.0; the TTM value through Mar 2026 reached $47000.0, changed N/A, while the annual FY2025 figure was $141000.0, 96.32% down from the prior year.
  • Other Non-Current Liabilities hit $47000.0 in Q1 2026 for Cartesian Therapeutics, down from $141000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $33.5 million in Q3 2022 and bottomed at $47000.0 in Q1 2026.
  • Average Other Non-Current Liabilities over 5 years is $12.6 million, with a median of $10.0 million recorded in 2022.
  • Year-over-year, Other Non-Current Liabilities soared 236.12% in 2023 and then tumbled 96.32% in 2025.
  • Cartesian Therapeutics' Other Non-Current Liabilities stood at $19.1 million in 2022, then tumbled by 66.59% to $6.4 million in 2023, then crashed by 40.01% to $3.8 million in 2024, then crashed by 96.32% to $141000.0 in 2025, then crashed by 66.67% to $47000.0 in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $47000.0, $141000.0, and $848000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.